Workflow
片仔癀药品
icon
Search documents
片仔癀:实施半年度约8.45亿元现金分红 分红总额同比增长22%
9月23日,片仔癀(600436.SH)发布2025年半年度权益分派实施公告。公告指出,此次A股每股将派发 现金红利1.40元(含税),股权登记日定为9月29日,现金红利发放日及除权(息)日为9月30日,分派 对象覆盖截至股权登记日下午上交所收市后登记在册的本公司全体股东。以方案实施前的公司总股本约 6.03亿股为基数,共计派发现金红利约8.45亿元(含税)。 (文章来源:证券时报网) 数据显示,2025年半年度,公司再度提升分红力度,分红占当前归母净利润比例从40.30%提升至 58.56%,当期分红总额8.45亿元相比2024年同期6.94亿元增长21.74%,与广大股东分享经营成果,进一 步提振投资者持股信心。 ...
片仔癀:2025年半年度权益分派实施公告
Zheng Quan Ri Bao· 2025-09-23 14:07
证券日报网讯 9月23日晚间,片仔癀发布公告称,2025年半年度利润分配方案为A股每股现金红利1.4元 (含税),股权登记日为2025年9月29日,除权(息)日为2025年9月30日。 (文章来源:证券日报) ...
频繁设立基金 片仔癀热衷投资
Bei Jing Shang Bao· 2025-08-07 15:39
Core Viewpoint - The company Pianzaihuang is actively investing in health-related industry funds to enhance its strategic development and competitiveness in the pharmaceutical sector [1][2][4]. Investment Activities - Pianzaihuang's subsidiary, Pianzaihuang Investment, plans to invest 200 million yuan in the Gaoxin Runxin Fund, representing 20% of the fund's target size [1][2]. - The Gaoxin Runxin Fund focuses on the healthcare sector, including pharmaceuticals, medical devices, and health-related supply chains, with non-healthcare investments capped at 10% [2]. - Since August of the previous year, Pianzaihuang has participated in multiple fund investments, including a similar 200 million yuan investment in the Yuanshan Health Industry Fund [2][3]. Financial Performance - In 2024, Pianzaihuang reported revenue of approximately 10.79 billion yuan, a year-on-year increase of 7.25%, and a net profit of about 2.98 billion yuan, up 6.42% [4]. - The company's gross margin decreased to 42.74% in 2024 from 46.76% the previous year, attributed to rising costs of key raw materials [4]. - In Q1 of this year, Pianzaihuang's revenue fell by 0.92% year-on-year to around 3.14 billion yuan, while net profit grew by 2.59% to about 1 billion yuan [4]. Strategic Outlook - The company aims to adapt to industry trends and improve risk management strategies, focusing on strategic reserves of key raw materials to enhance profit levels [5]. - Experts suggest that diversifying into emerging fields like synthetic biology and consumer healthcare through fund investments could provide new growth opportunities and reduce reliance on traditional products [5].